I-Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8 Purity >98.0% (GC) I-Lenvatinib Mesylate Intermediate Factory

Incazelo emfushane:

Igama Lekhemikhali: Methyl 4-Amino-2-Methoxybenzoate

I-CAS: 27492-84-8

Ubumsulwa: >98.0% (GC)

Ukubukeka: Impushana emhlophe iye kokumhlophe noma amakristalu

I-Intermediate ye-Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com


Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

Chemical Properties:

Igama Lekhemikhali I-Methyl 4-Amino-2-Methoxybenzoate
Omqondofana 4-Amino-2-Methoxybenzoic Acid Methyl Ester;I-Methyl 4-Amino-o-Anisate;4-Amino-o-Anisic Acid Methyl Ester
Inombolo ye-CAS 27492-84-8
Inombolo yeCAT I-RF-PI1974
Isimo Sesitoko Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani
I-Molecular Formula I-C9H11NO3
Isisindo samangqamuzana 181.19
Ukuminyana 1.179±0.060 g/cm3
Ibhrendi I-Ruifu Chemical

Imininingwane:

Into Imininingwane
Ukubukeka Impushana emhlophe ukuya kokumhlophe noma amakristalu
Ukuhlanzeka / Indlela Yokuhlaziya >98.0% (GC)
Ukuhlanzeka / Indlela Yokuhlaziya 97.5~102.5 (Nonaqueous Titration)
I-Melting Point 157.0 ~ 161.0℃
Ukulahlekelwa Ekumisweni <1.00%
Ukungcola Okuphelele <2.0%
I-Infrared Spectrum Ivumelana Nesakhiwo
I-Proton NMR Spectrum Ivumelana Nesakhiwo
Izinga Lokuhlola I-Enterprise Standard
Ukusetshenziswa I-Intermediate ye-Lenvatinib Mesylate (CAS: 857890-39-2)

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama

Izinzuzo:

1

I-FAQ:

Isicelo:

I-Methyl 4-Amino-2-Methoxybenzoate (i-CAS: 27492-84-8) ingasetshenziswa njengendawo ephakathi ye-Lenvatinib Mesylate (CAS: 857890-39-2).I-Lenvatinib iyisidakamizwa somdlavuza we-thyroid esakhiwe yi-Eisai Corporation yaseJapane (Ikhodi: E7080), eyingxenye ye-inhibitor ye-oral multi-receptor tyrosine kinase (RTK) futhi ingavimbela umsebenzi we-kinase we-vascular endothelial growth factor (VEGF) Receptors VEGFR1 ( I-FLT1), i-VEGFR2 (KDR), ne-VEGFR3 (FLT4).I-Lenvatinib ingaphinde ivimbele ukubandakanyeka kwamanye ama-RTK ku-angiogenesis ye-pathological, ukukhula kwesimila, nokuqhubeka komdlavuza ngaphandle kwemisebenzi yawo evamile yamaselula kuhlanganise ne-fibroblast growth factor (FGF) receptors FGFR1, 2, 3, kanye ne-4;i-platelet-derived growth factor receptor (PDGFR [alpha]), i-KIT, ne-RET.[Izinkomba]: I-Lenvatinib ifanelekela ukwelapha iziguli ezinomdlavuza wegilo wokuphindaphinda kwendawo noma uhlobo lwe-metastasis, uhlobo lwe-progressivity kanye nohlobo oluhlukanisiwe lwe-radioactive iodine-refractory.NgoFebhuwari 13, 2015, i-US FDA yagunyaza isidakamizwa esilwa nomdlavuza i-Lenvatinib sokwelapha umdlavuza wegilo.I-Lenvatinib iyi-multi-target enzyme inhibitor, ekwazi ukuvimbela i-VEGFR2 ne-VEGFR3 (i-vascular endothelial growth factor receptor).Igama lokuhweba le-Lenvatinib yi-Lenvima.Ngomhla zingama-20 kuNhlaba wezi-2015, i-European Medicines Agency (EMA) igunyaze i-Lenvatinib yokwelashwa komdlavuza wegilo wegilo (DTC) ohlaselayo, othuthuke kakhulu noma ometastatic (papillary, follicular, Hurthle type) thyroid cancer (DTC).Ocwaningweni, isikhathi esimaphakathi sokusinda kweziguli ezine-radioactive iodine-refractory DTC ezilashwe nge-Lenvatinib kwakuyizinyanga eziyi-18 kanti inani leziguli ezithatha i-placebo yizinyanga ezi-3 kuphela.

Bhala umyalezo wakho lapha futhi usithumelele wona